Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
Go back to Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 158.07 +12.45 (8.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.62 | 52 Week High | $0.52 | |||
| Open | $152.50 | 52 Week Low | $0.08 | |||
| Day High | $161.96 | P/E | N/A | |||
| Day Low | $149.50 | EPS | $-3.80 | |||
| Volume | 19,213,060 | |||||
